Regencell Bioscience (RGC) Competitors $15.40 +0.11 (+0.72%) As of 10:33 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RGC vs. ARGX, ONC, BNTX, TEVA, INSM, SMMT, ITCI, GMAB, MRNA, and RDYShould you be buying Regencell Bioscience stock or one of its competitors? The main competitors of Regencell Bioscience include argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Regencell Bioscience vs. Its Competitors argenex BeOne Medicines BioNTech Teva Pharmaceutical Industries Insmed Summit Therapeutics Intra-Cellular Therapies Genmab A/S Moderna Dr. Reddy's Laboratories argenex (NASDAQ:ARGX) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings. Which has higher valuation and earnings, ARGX or RGC? argenex has higher revenue and earnings than Regencell Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioargenex$2.25B15.43$833.04M$16.2135.03Regencell BioscienceN/AN/A-$4.30MN/AN/A Is ARGX or RGC more profitable? argenex has a net margin of 40.20% compared to Regencell Bioscience's net margin of 0.00%. argenex's return on equity of 16.15% beat Regencell Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets argenex40.20% 16.15% 14.33% Regencell Bioscience N/A N/A N/A Which has more volatility & risk, ARGX or RGC? argenex has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Regencell Bioscience has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500. Do analysts prefer ARGX or RGC? argenex presently has a consensus target price of $728.06, suggesting a potential upside of 28.23%. Given argenex's stronger consensus rating and higher probable upside, equities analysts clearly believe argenex is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score argenex 0 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 2 Strong Buy rating(s) 3.10Regencell Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in ARGX or RGC? 60.3% of argenex shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to ARGX or RGC? In the previous week, argenex had 11 more articles in the media than Regencell Bioscience. MarketBeat recorded 14 mentions for argenex and 3 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.38 beat argenex's score of 1.21 indicating that Regencell Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summaryargenex beats Regencell Bioscience on 12 of the 14 factors compared between the two stocks. Get Regencell Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for RGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGC vs. The Competition Export to ExcelMetricRegencell BioscienceMedicinal Chemicals IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$6.77B$6.77B$2.17B$9.35BDividend YieldN/AN/A2.60%4.09%P/E RatioN/AN/A22.2719.83Price / SalesN/AN/A105.45106.18Price / CashN/AN/A13.2957.53Price / Book770.00797.5081.295.72Net Income-$4.30M-$4.30M-$127.36M$257.51M7 Day Performance-7.06%-3.74%0.42%0.59%1 Month PerformanceN/AN/A1.96%10.74%1 Year PerformanceN/AN/A21.38%15.87% Regencell Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGCRegencell Bioscience0.3405 of 5 stars$15.40+0.7%N/AN/A$6.77BN/A0.0010Positive NewsGap UpARGXargenex4.4997 of 5 stars$543.84+1.0%$728.06+33.9%+22.5%$33.23B$2.25B33.571,599Positive NewsUpcoming EarningsAnalyst RevisionONCBeOne Medicines2.5101 of 5 stars$252.85+3.4%$320.67+26.8%N/A$27.71B$3.81B-67.9711,000Analyst ForecastGap UpBNTXBioNTech1.4746 of 5 stars$111.31-0.3%$137.86+23.9%+29.6%$26.82B$2.98B-32.816,772Analyst ForecastTEVATeva Pharmaceutical Industries4.0903 of 5 stars$16.82+1.1%$24.13+43.5%-3.9%$19.29B$16.62B-14.6236,830Positive NewsINSMInsmed3.8363 of 5 stars$96.73+0.6%$108.07+11.7%+34.1%$18.34B$363.71M-16.251,271Analyst ForecastInsider TradeSMMTSummit Therapeutics1.9585 of 5 stars$24.17+5.1%$34.67+43.5%+210.0%$17.89B$700K-70.84110ITCIIntra-Cellular Therapies0.9163 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9269 of 5 stars$21.48+1.1%$37.80+75.9%-19.0%$13.77B$3.12B12.202,682Analyst RevisionMRNAModerna4.2711 of 5 stars$32.26-0.9%$46.61+44.5%-74.4%$12.46B$3.24B-3.695,800Analyst RevisionRDYDr. Reddy's Laboratories2.77 of 5 stars$14.75-0.2%$16.95+15.0%-6.7%$12.30B$3.81B22.3327,811News Coverage Related Companies and Tools Related Companies ARGX Competitors ONC Competitors BNTX Competitors TEVA Competitors INSM Competitors SMMT Competitors ITCI Competitors GMAB Competitors MRNA Competitors RDY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGC) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regencell Bioscience Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Regencell Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGC Stock Alerts